Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 8214

1.

Reprogramming of the ERRα and ERα target gene landscape triggers tamoxifen resistance in breast cancer.

Thewes V, Simon R, Schroeter P, Schlotter M, Anzeneder T, Büttner R, Benes V, Sauter G, Burwinkel B, Nicholson RI, Sinn HP, Schneeweiss A, Deuschle U, Zapatka M, Heck S, Lichter P.

Cancer Res. 2015 Feb 15;75(4):720-31. doi: 10.1158/0008-5472.CAN-14-0652. Epub 2015 Feb 2.

PMID:
25643697
2.

A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.

Jerusalem G, Bachelot T, Barrios C, Neven P, Di Leo A, Janni W, de Boer R.

Cancer Treat Rev. 2015 Feb;41(2):94-104. doi: 10.1016/j.ctrv.2014.12.011. Epub 2014 Dec 30. Review.

PMID:
25575443
3.

Blockade of estrogen-stimulated proliferation by a constitutively-active prolactin receptor having lower expression in invasive ductal carcinoma.

Huang KT, Tan D, Chen KH, Walker AM.

Cancer Lett. 2015 Mar 28;358(2):152-60. doi: 10.1016/j.canlet.2014.12.031. Epub 2014 Dec 16.

PMID:
25527452
4.

Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.

Bhola NE, Jansen VM, Bafna S, Giltnane JM, Balko JM, Estrada MV, Meszoely I, Mayer I, Abramson V, Ye F, Sanders M, Dugger TC, Allen EV, Arteaga CL.

Cancer Res. 2015 Jan 15;75(2):405-14. doi: 10.1158/0008-5472.CAN-14-2475. Epub 2014 Dec 5.

PMID:
25480943
5.

Modeling prolactin actions in breast cancer in vivo: insights from the NRL-PRL mouse.

O'Leary KA, Shea MP, Schuler LA.

Adv Exp Med Biol. 2015;846:201-20. doi: 10.1007/978-3-319-12114-7_9.

PMID:
25472540
6.

Ceramide synthases CerS4 and CerS5 are upregulated by 17β-estradiol and GPER1 via AP-1 in human breast cancer cells.

Wegner MS, Wanger RA, Oertel S, Brachtendorf S, Hartmann D, Schiffmann S, Marschalek R, Schreiber Y, Ferreirós N, Geisslinger G, Grösch S.

Biochem Pharmacol. 2014 Dec 15;92(4):577-89. doi: 10.1016/j.bcp.2014.10.007. Epub 2014 Oct 22.

PMID:
25451689
7.

Cytochrome P450 1 family and cancers.

Go RE, Hwang KA, Choi KC.

J Steroid Biochem Mol Biol. 2015 Mar;147:24-30. doi: 10.1016/j.jsbmb.2014.11.003. Epub 2014 Nov 6. Review.

PMID:
25448748
8.

Fetal alcohol exposure and mammary tumorigenesis in offspring: role of the estrogen and insulin-like growth factor systems.

Cohick WS, Crismale-Gann C, Stires H, Katz TA.

Adv Exp Med Biol. 2015;815:403-24. doi: 10.1007/978-3-319-09614-8_24. Review.

PMID:
25427921
9.

[Nuclear Medicine in diagnosis of breast cancer].

Iakovou IP, Giannoula E.

Hell J Nucl Med. 2014 Sep-Dec;17(3):221-7. doi: 10.1967/s002449910150. Epub 2014 Nov 12. Review. Greek, Modern.

10.
11.
12.

Early pregnancy sex steroids and maternal breast cancer: a nested case-control study.

Fortner RT, Schock H, Kaaks R, Lehtinen M, Pukkala E, Lakso HÅ, Tanner M, Kallio R, Joensuu H, Grankvist K, Zeleniuch-Jacquotte A, Toniolo P, Lundin E, Surcel HM.

Cancer Res. 2014 Dec 1;74(23):6958-67. doi: 10.1158/0008-5472.CAN-14-2150. Epub 2014 Oct 3.

PMID:
25281720
13.

Bioenergetic differences between MCF-7 and T47D breast cancer cells and their regulation by oestradiol and tamoxifen.

Radde BN, Ivanova MM, Mai HX, Salabei JK, Hill BG, Klinge CM.

Biochem J. 2015 Jan 1;465(1):49-61. doi: 10.1042/BJ20131608.

PMID:
25279503
14.

Pharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients.

Maximov PY, McDaniel RE, Fernandes DJ, Bhatta P, Korostyshevskiy VR, Curpan RF, Jordan VC.

J Natl Cancer Inst. 2014 Sep 24;106(10). pii: dju283. doi: 10.1093/jnci/dju283. Print 2014 Oct.

PMID:
25258390
15.

Intratumoral heterogeneity of breast cancer xenograft models: texture analysis of diffusion-weighted MR imaging.

Yun BL, Cho N, Li M, Jang MH, Park SY, Kang HC, Kim B, Song IC, Moon WK.

Korean J Radiol. 2014 Sep-Oct;15(5):591-604. doi: 10.3348/kjr.2014.15.5.591. Epub 2014 Sep 12.

16.

Intratumoral androgen metabolism and actions in invasive lobular carcinoma of the breast.

Yoda T, McNamara KM, Miki Y, Takagi M, Rai Y, Ohi Y, Sagara Y, Tamaki K, Hirakawa H, Ishida T, Suzuki T, Ohuchi N, Sasano H.

Cancer Sci. 2014 Nov;105(11):1503-9. doi: 10.1111/cas.12535. Epub 2014 Nov 7.

PMID:
25230018
17.

The wedelolactone derivative inhibits estrogen receptor-mediated breast, endometrial, and ovarian cancer cells growth.

Xu D, Lin TH, Yeh CR, Cheng MA, Chen LM, Chang C, Yeh S.

Biomed Res Int. 2014;2014:713263. doi: 10.1155/2014/713263. Epub 2014 Aug 13.

18.

Modification of ASC1 by UFM1 is crucial for ERα transactivation and breast cancer development.

Yoo HM, Kang SH, Kim JY, Lee JE, Seong MW, Lee SW, Ka SH, Sou YS, Komatsu M, Tanaka K, Lee ST, Noh DY, Baek SH, Jeon YJ, Chung CH.

Mol Cell. 2014 Oct 23;56(2):261-74. doi: 10.1016/j.molcel.2014.08.007. Epub 2014 Sep 11.

PMID:
25219498
19.

Human glutathione S-transferase P1-1 functions as an estrogen receptor α signaling modulator.

Liu X, An BH, Kim MJ, Park JH, Kang YS, Chang M.

Biochem Biophys Res Commun. 2014 Sep 26;452(3):840-4. doi: 10.1016/j.bbrc.2014.09.017. Epub 2014 Sep 16.

PMID:
25218501
20.

ER-α variant ER-α36 mediates antiestrogen resistance in ER-positive breast cancer stem/progenitor cells.

Deng H, Yin L, Zhang XT, Liu LJ, Wang ML, Wang ZY.

J Steroid Biochem Mol Biol. 2014 Oct;144 Pt B:417-26. doi: 10.1016/j.jsbmb.2014.08.017. Epub 2014 Aug 23.

PMID:
25158023
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk